



London, May 2002
CPMP/QWP/158/01 Revision
EMA/ CVMP/115/01 Revision

**COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP)
COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS (CVMP)**

**NOTE FOR GUIDANCE ON QUALITY OF WATER FOR
PHARMACEUTICAL USE**

DISCUSSION IN THE QUALITY WORKING PARTY (QWP)	October 2000, January 2001
TRANSMISSION TO THE CPMP/CVMP	February 2001
RELEASE FOR CONSULTATION	February 2001
DEADLINE FOR COMMENTS	August 2001
DISCUSSION IN THE QUALITY WORKING PARTY (QWP)	October 2001
TRANSMISSION TO CPMP/CVMP	November 2001
ADOPTION BY CPMP /CVMP	November 2001
DISCUSSION IN QWP FOLLOWING INDUSTRY REPRESENTATION	April 2002
MODIFICATION TO TABLES 3 AND 5	
ADOPTION BY CPMP/CVMP	May 2002
DATE FOR COMING INTO OPERATION	1 June 2002

Changes are in:

- Table 3 (Final isolation and purification of API - not sterile but intended for use in sterile parenteral product)
- Table 5 - Initial rinse of containers/closures for sterile products
- Table 5 - Final rinse of containers closures for sterile parenteral products (addition of footnote).

7 Westferry Circus, Canary Wharf, London, E14 4HB, UK
Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 85 95
E-mail: mail@emea.eu.int http://www.emea.eu.int

©EMA 2001 Reproduction and/or distribution of this document is authorised for non commercial purposes only provided the EMA is acknowledged

NOTE FOR GUIDANCE ON QUALITY OF WATER FOR PHARMACEUTICAL USE

1. INTRODUCTION

Water is one of the major commodities used by the pharmaceutical industry. It may be present as an excipient, or used for reconstitution of products, during synthesis, during production of the finished product or as a cleaning agent for rinsing vessels, equipment, primary packaging materials etc.

Different grades of water quality are required depending on the different pharmaceutical uses. Control of the quality of water, in particular, the microbiological quality, is a major concern and the pharmaceutical industry devotes considerable resource to the development and maintenance of water purification systems.

2. BACKGROUND

The European Pharmacopoeia (Ph Eur) contains standards for grades of water for pharmaceutical use including Water for Injections (WFI) and Purified Water. The use of reverse osmosis (RO) as a means of preparing WFI has been the subject of ongoing discussion within the Ph Eur Commission for a number of years. In 1999, in response to requests from national delegations to permit the use of RO for WFI production, a major international symposium was organised to discuss the issue. The meeting concluded that there was insufficient evidence at the present time to support the use of RO to produce WFI and in view of the safety concerns, WFI should be prepared only by distillation as laid down in the Ph Eur.

The meeting agreed that further guidance on the use of the different grades of pharmaceutical water would be beneficial to the industry as the Ph Eur monographs themselves do not address some of the aspects of when particular grades should be used. Furthermore as a result of this activity a new Ph Eur monograph entitled 'Highly Purified Water' has been adopted and will be implemented in the Ph Eur from 1st January 2002.

The CPMP/CVMP Quality Working Party and Inspectors Working Party have recently reconsidered the use of RO water for the preparation of WFI. They have concluded on the available evidence, that the production of water by RO and associated technologies is considered to lack the robustness of distillation and concerns remain about the potential risks associated with, for example, fouling of the membrane (chemical and biological), failure of membrane integrity and lack of effective validation. Hence the current view is that Highly Purified Water is not acceptable for WFI.

3. SCOPE

This document is intended to provide guidance to the industry on the pharmaceutical use of different grades of water in the manufacture of active pharmaceutical ingredients and medicinal products for human and veterinary use.

This guidance is not intended to cover situations where, for example, medicinal products are prepared extemporaneously or where preparations are reconstituted/diluted with water prior to use by a pharmacist (eg. oral antibiotic mixtures) or in the case of veterinary products, by the user (eg. sheep dips).

4. REQUIREMENTS OF THE EUROPEAN PHARMACOPOEIA

The European Pharmacopoeia provides standards for the following grades of water:

- Water for Injections
- Purified Water
- Highly Purified Water

4.1 Potable Water is not covered by a pharmacopoeial monograph but must comply with the regulations on water laid down by the competent authority. Testing should be carried out at the manufacturing site to confirm the quality of the water. Potable water may be used in chemical synthesis and in the early stages of cleaning pharmaceutical manufacturing equipment unless there are specific technical or quality requirements for higher grades of water. It is the prescribed source feed water for the production of pharmacopoeial grade waters.

4.2 Water for Injections (WFI) is water for the preparation of medicines for parenteral administration when water is used as a vehicle (water for injections in bulk) and for dissolving or diluting substances or preparations for parenteral administration before use (sterilised water for injections).

Production

Control of the chemical purity of WFI presents few major problems. The critical issue is that of ensuring consistent microbiological quality with respect to removal of bacteria and bacterial endotoxins. Distillation has a long history of reliable performance and can be validated as a unit operation, hence it currently remains the only official method for WFI.

WFI in bulk is obtained from water that complies with the regulation on water intended for human consumption laid down by the competent authority, or from purified water, by distillation in an apparatus of which the parts in contact with the water are of neutral glass, quartz or suitable metal and which is fitted with an effective device to prevent the entrainment of droplets. The correct maintenance of the apparatus is essential. During production and storage, appropriate measures are taken to ensure that the total viable aerobic count is adequately controlled and monitored.

WFI complies with the tests for Purified Water with additional requirements for bacterial endotoxins (not more than (nmt) 0.25 IU of endotoxin per ml), conductivity and Total Organic Carbon.

4.3 Purified Water is water for the preparation of medicinal products other than those that require the use of water which is sterile and/or apyrogenic. Purified Water which satisfies the test for endotoxins may be used in the manufacture of dialysis solutions.

Production

Purified Water is prepared by distillation, by ion exchange or by any other suitable method, from water that complies with the regulations on water intended for human consumption laid down by the competent authority.

4.4 Highly Purified Water is intended for use in the preparation of products where water of high biological quality is needed, except where Water for Injections is required.

Production

Highly Purified Water is obtained from water that complies with the regulations on water intended for human consumption laid down by the competent authority. Current production methods include, for example, double-pass reverse osmosis coupled with other suitable

techniques such as ultrafiltration and deionisation. Highly Purified Water meets the same quality standards as WFI but the production methods are considered less reliable than distillation and thus it is considered unacceptable for use as WFI.

5. QUALITY OF WATER FOR PHARMACEUTICAL USE

Validation and qualification of water purification, storage and distribution systems are a fundamental part of GMP and form an integral part of the GMP inspection.

The grade of water used at different stages in the manufacture of the active pharmaceutical ingredients and pharmaceutical products should be discussed in the pharmaceutical dossier. The grade of water used should take account of the nature and intended uses of the finished product and the stage at which the water is used.

The following tables provide some general examples for guidance:

5.1 Water present as an excipient in the final formulation

Water is the most commonly used excipient in medicinal products: the minimum quality of water selected depends on the intended use of the product. Table 1 summarises the main categories of sterile products. WFI is required for those products intended for parenteral administration and this includes solutions for haemofiltration and haemodiafiltration, and peritoneal dialysis.

For convenience the pharmaceutical industry often uses WFI for the preparation of ophthalmic, sterile nasal/ear and cutaneous preparations. In such situations, Highly Purified Water represents a useful alternative with the added advantage of satisfying the industry's need for large volumes.

Table 1: Sterile Medicinal Products

Sterile medicinal products	Minimum acceptable quality of water
Parenteral	WFI
Ophthalmic	Purified
Haemofiltration Solutions Haemodiafiltration Solutions	WFI
Peritoneal Dialysis Solutions	WFI
Irrigation Solutions	WFI
Nasal/Ear Preparations	Purified
Cutaneous Preparations	Purified

Table 2 summarises the main categories of non-sterile dosage forms. With the exception of some nebuliser preparations, Purified Water is the acceptable grade of water for all non-sterile products.

Table 2: Non-sterile Medicinal Products

Non-sterile medicinal products	Minimum acceptable quality of water
Oral Preparations	Purified
Nebuliser Solutions	Purified*
Cutaneous Preparations	Purified **
Nasal/Ear Preparations	Purified
Rectal/Vaginal Preparations	Purified

* In certain disease states eg. cystic fibrosis, medicinal products administered by nebulisation are required to be sterile and non-pyrogenic. In such cases WFI or sterilised Highly Purified Water should be used.

** For some products such as veterinary teat dips it may be acceptable to use potable water where justified and authorised taking account of the variability in chemical composition and microbiological quality.

5.2 Water used during manufacture of active pharmaceutical ingredients and medicinal products excluding water present as an excipient in the final formulation

The acceptable grade of water will depend heavily on the stage at which it is to be used during manufacture, the subsequent processing steps and the nature of the final product. Tables 3 and 4 summarise the acceptable quality of water for the manufacture of active pharmaceutical ingredients and for sterile and non-sterile medicinal products.

Table 3: Water used during the manufacture of Active Pharmaceutical Ingredients (APIs)

Type of manufacture	Product requirements	Minimum acceptable quality of water
Synthesis of all intermediates of APIs prior to final isolation and purification steps	No requirement for sterility or apyrogenicity in API or the pharmaceutical product in which it will be used.	Potable Water*
Fermentation media	No requirement for sterility or apyrogenicity in API or the pharmaceutical product in which it will be used	Potable Water*
Extraction of herbals	No requirement for sterility or apyrogenicity in API or the pharmaceutical product in which it will be used	Potable Water**
Final isolation and purification	No requirement for sterility or apyrogenicity in API or the pharmaceutical product in which it will be used	Potable Water*
Final isolation and purification	API is not sterile, but is intended for use in a sterile, non-parenteral product	Purified Water
Final isolation and purification	API is sterile and not intended for parenteral use	Purified Water
Final isolation and purification	API is not sterile, but is intended for use in a sterile, parenteral product	Purified Water with an endotoxin limit of 0.25EU/ml and control of specified organisms.
Final isolation and purification	API is sterile and apyrogenic	Water For Injections

* Purified Water should be used where there are technical requirements for greater chemical purity.

** The Applicant would need to demonstrate that potential variations in the water quality, particularly with respect to mineral composition, would not influence the composition of the extract.

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.